Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Specimen Handling 479pembrolizumab 454Magnetic Resonance Spectroscopy 421Carboplatin 327Cyclophosphamide 313Cisplatin 271Biopsy 270Radiotherapy 245Paclitaxel 230Gemcitabine 228Bevacizumab 211Nivolumab 188fludarabine 185venetoclax 174Drug Therapy 170Dexamethasone 158Blood Specimen Collection 158Oxaliplatin 155Injections 152Capecitabine 152Fluorouracil 144Docetaxel 142Standard of Care 135Radiosurgery 135Rituximab 125Pemetrexed 118durvalumab 115Leucovorin 108Radiation 107atezolizumab 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Omacor × 1 year × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡